Automotive Stocks Earnings Alert - Worksport Ltd. (NASDAQ: $WKSP) November 13th ; @WorksportLtd

 

 

 

 

 

Automotive Stocks Earnings Alert - Worksport Ltd. (NASDAQ: $WKSP) November 13^th ; @WorksportLtd

 

  

November 11, 2024 - Investorideas.com, a go-to investing platform covering automotive stocks releases an investor and media  alert for upcoming Earnings call with Worksport Ltd. (NASDAQ: WKSP) , a U.S.-based manufacturer and innovator of hybrid and clean energy solutions for the light truck, overlanding, and global consumer goods sectors.

 

The Q3 2024 live earnings call is scheduled for November 13, 2024, at 4:30 PM ET.

Sign up link WKSP Q3 Earnings Call

 

As automotive stocks are trending following the US election results and U.S.-based automakers, particularly General Motors ( NYSE: GM ) and Ford ( NYSE: F) are positioned to benefit from the new Trump administration; investors can hear management discuss earnings and projections.

 

Additionally being a U.S.-based manufacturer puts Worksport in an advantageous tax position for the future under Trump.

 

Paid News Dissemination of behalf of WKSP

 

Read this news, featuring WKSP in full at https://www.investorideas.com/news/2024/auto/11111Automotive-Stocks-WKSP-Earnings.asp

 

 

From the news- Expected Topics

 

In Q3 2024, the Company has had significant developments and milestones. While specific details will be shared during the call, attendees can look forward to insights into our recent achievements, strategic initiatives, and projected path to cash flow positivity. This includes updates on the Company’s ongoing sales growth, future product launches, and 2025 growth trajectory. The Company will also provide an update to its financial guidance.

 

CEO's Statement

 

“We are thrilled to invite investors and analysts to our Q3 live earnings call,” said Steven Rossi, CEO of Worksport. “We started mass production in January 2024 and initiated our sales push in March 2024. Now, we are on the cusp of launching multiple new product lines. The Company is laser-focused on continuing sales growth and achieving cash flow positivity, and we are eager to share the details of our progress and future plans. We confidently believe that the Company is undervalued and that growth will continue.”

 

Full press release here

From previous news on October 23:

 

Strategic Impact on Revenue Growth

 

Worksport anticipates that the introduction of the AL4 cover will significantly impact revenue growth in 2025 and beyond. With the AL4 cover believed to be targeting the highest-volume category of all hard tonneau covers in the $4 billion market, the Company aims to aggressively capture market share. A sales forecast update is expected to be provided within Q4 2024 or early Q1 2025.

 

Initial offering will cover major brands including Chevrolet, GMC, Ford, Ram, with the following truck applications:

 

Chevrolet & GMC: Models for the GMC Canyon / Chevrolet Colorado / Chevrolet Silverado

 

Ford: Ford Ranger and Ford Super Duty models.

 

Ram: Ram 1500

 

WKSP Pickup tonneau cover

 

Interested investors and media can sign up here WKSP Q3 Earnings Call

 

 

About Worksport Ltd.

Worksport Ltd. (NASDAQ: WKSP), through its subsidiaries, designs, develops, manufactures, and owns the intellectual property on a variety of tonneau covers, solar integrations, portable energy storage systems, and heat-pump technology. The Company is committed to transforming the pickup truck industry through innovative technologies that enhance functionality and sustainability.

 

For more information, please visit www.worksport.com  | investors.worksport.com | https://terravisenergy.com

 

Follow the Company’s social media accounts on X (previously Twitter), Facebook, LinkedIn, YouTube, and Instagram ), the links of which are links to external third party websites, as well as sign up for the Company’s newsletters at investors.worksport.com.

 

The Company does not endorse, ensure the accuracy of, or accept any responsibility for any content on these third-party websites other than content published by the Company.

 

Read the company’s forward looking statement on their recent news release .

 

About Investorideas.com - Big Investing Ideas

Investorideas.com is the go-to platform for big investing ideas. From breaking stock news to top-rated investing podcasts, we cover it all. Our original branded content includes podcasts such as Exploring Mining, Cleantech, Crypto Corner, Cannabis News, and the AI Eye. We also create free investor stock directories for sectors including mining, crypto, renewable energy, gaming, biotech, tech, sports and more. Public companies within the sectors we cover can use our news publishing and content creation services to help tell their story to interested investors. Paid content is always disclosed.

 

Disclaimer/Disclosure: Disclosure: this news article featuring WKSP is a paid for service  on Investorideas.com -.  This is not investment opinion: Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. - More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy:

https://www.investorideas.com/About/Private_Policy.asp    

Learn more about our news, PR and social media, podcast sponsorship and ticker tag services at Investorideas.com

https://www.investorideas.com/Investors/Services.asp

Learn more about digital advertising and guest posts

https://www.investorideas.com/Advertise/

 

Follow us on Twitter @investorideas

Follow us on Facebook https://www.facebook.com/Investorideas

Follow us on YouTube https://www.youtube.com/c/Investorideas

 

Contact Investorideas.com

800-665-0411

 

Get more Renewable Energy Stock news, articles, podcasts and Stock Directories

 

  

 

 

Get more Automotive Stocks Investor Ideas – news, articles and stock directories  

Breaking Medical Technology News: Aethlon Medical (NASDAQ: $AEMD) Reaches Key Milestone with Enrollment of the First Patient in (FPI) Its Hemopurifier® Cancer Trial in Australia

 

 

 

 

Breaking Medical Technology News: Aethlon Medical (NASDAQ: $AEMD) Reaches Key Milestone with Enrollment of the First Patient in (FPI) Its Hemopurifier® Cancer Trial in Australia

 

Patient Enrolled at the Cancer Clinical Trial Unit, CALHN, Royal Adelaide Hospital

 

Aethlon’s Trial is a Safety, Feasibility, and Dose Finding Study of the Hemopurifier® in Patients with Solid Tumors Not Responding to Anti-PD-1 Antibodies

 

SAN DIEGO, CA - November 11, 2024 (Investorideas.com Newswire) Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced enrollment of the first patient in its Australian safety, feasibility and dose-finding clinical trial of the Hemopurifier® in patients with solid tumors who have stable or progressive disease during anti-PD-1 monotherapy treatment, such as Keytruda® (pembrolizumab) or Opdivo® (nivolumab) (AEMD-2022-06 Hemopurifier Study). The patient was enrolled on October 29, 2024, by Prof. Michael Brown and his staff at the Cancer Clinical Trials Unit, CALHN, Royal Adelaide Hospital in Australia.

 

The first patient completed screening activities confirming their eligibility on November 8, 2024, and has now entered a two-month run-in period, receiving anti-PD-1 therapy. During this time, concentrations of Extracellular vesicles (EVs) and anti-tumor T cell activity will be measured. If imaging after this two-month run-in period reveals no improvement in the patient’s tumor, they will be treated with the Hemopurifier, followed by monitoring to identify decreases in EV concentrations and improvements in T cell anti-tumor activity.

 

Paid News Dissemination of behalf of AEMD

Read this news, featuring AEMD in full at https://www.investorideas.com/news/2024/11111AEMD-Hemopurifier-Cancer-Trial-Australia.asp

"Enrollment of the first patient represents the achievement of a critical milestone for Aethlon Medical in the clinical development of the Hemopurifier in Oncology,” stated Steven LaRosa, MD, Chief Medical Officer of Aethlon Medical. “We are thrilled with the pre-screening activity being done to identify patients at Royal Adelaide, as well as the second site, Pindara Private Hospital in the Gold Coast. We are grateful to the patient for consenting to be part of this study. This trial is our initial step in determining if the Hemopurifier treatment can improve upon the 30-40% response rates to anti-PD-1 therapies such as Opdivo and Keytruda.”  

 

Currently, only approximately 30% of patients who receive pembrolizumab or nivolumab will have lasting clinical responses to these agents. EVs produced by tumors have been implicated in the spread of cancers as well as the resistance to anti-PD-1 therapies. The Aethlon Hemopurifier has been designed to bind and remove these EVs from the bloodstream, which may improve therapeutic response rates to anti-PD-1 antibodies. In preclinical studies, the Hemopurifier has been shown to reduce the number of exosomes from the plasma of cancer patient samples.

 

The primary endpoint of the approximately nine to 18-patient, safety, feasibility and dose-finding trial is the incidence of adverse events and clinically significant changes in safety lab tests of Hemopurifier treated patients with solid tumors with stable or progressive disease at different treatment intervals, after a two-month run in period of PD-1 antibody, Keytruda® or Opdivo® monotherapy. Patients who do not respond to the therapy will be eligible to enter the Hemopurifier period of the study where sequential cohorts will receive 1, 2 or 3 Hemopurifier treatments during a one-week period. In addition to monitoring safety, the study is designed to examine the number of Hemopurifier treatments needed to decrease the concentration of EVs and if these changes in EV concentrations improve the body’s own natural ability to attack tumor cells. These exploratory central laboratory analyses are expected to inform the design of a subsequent efficacy and safety, Premarket Approval (PMA), study required by regulatory agencies.

 

About Aethlon and the Hemopurifier®

Aethlon Medical is a medical therapeutic company focused on developing the Hemopurifier, a clinical stage immunotherapeutic device which is designed to combat cancer and life-threatening viral infections and for use in organ transplantation. In human studies, the Hemopurifier has demonstrated the removal of life-threatening viruses and in pre-clinical studies, the Hemopurifier has demonstrated the removal of harmful exosomes from biological fluids, utilizing its proprietary lectin-based technology. This action has potential applications in cancer, where exosomes may promote immune suppression and metastasis, and in life-threatening infectious diseases. The Hemopurifier is a U.S. Food and Drug Administration (FDA) designated Breakthrough Device indicated for the treatment of individuals with advanced or metastatic cancer who are either unresponsive to or intolerant of standard of care therapy, and with cancer types in which exosomes have been shown to participate in the development or severity of the disease. The Hemopurifier also holds an FDA Breakthrough Device designation and an open Investigational Device Exemption (IDE) application related to the treatment of life-threatening viruses that are not addressed with approved therapies.

 

Additional information can be found at www.AethlonMedical.com.

 

Forward Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that involve risks and uncertainties. Statements containing words such as "may," "believe," "anticipate," "expect," "intend," "plan," "project," "will," "projections," "estimate," "potentially" or similar expressions constitute forward-looking statements. Such forward-looking statements are subject to significant risks and uncertainties and actual results may differ materially from the results anticipated in the forward-looking statements. These forward-looking statements are based upon Aethlon's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Factors that may contribute to such differences include, without limitation, the Company's ability to raise additional capital on terms favorable to the Company, or at all; the Company's ability to successfully complete development of the Hemopurifier; the Company's ability to successfully demonstrate the utility of the Hemopurifier in patients with solid tumors in our oncology clinical trials; the Company’s ability to achieve and realize the anticipated benefits from potential milestones; the Company’s ability to obtain approval from the Ethics Committee of its third location in Australia, including on the timeline expected by the Company; the Company’s ability to enroll additional patients in its oncology clinical trials in Australia and India, including on the timeline expected by the Company; whether or not patients that are enrolled in the Company’s clinical trials will respond to PD-1 antibody monotherapy; the number of patients that are enrolled in the Company’s clinical trials that will ultimately be treated with the Company’s Hemopurifier; the Company’s ability to manage and successfully complete its clinical trials; the Company’s ability to successfully manufacture the Hemopurifier in sufficient quantities for its clinical trials; and other potential risks. The foregoing list of risks and uncertainties is illustrative but is not exhaustive. Additional factors that could cause results to differ materially from those anticipated in forward-looking statements can be found under the caption "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended March 31, 2023, and in the Company's other filings with the Securities and Exchange Commission, including its quarterly Reports on Form 10-Q. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except as may be required by law, the Company does not intend, nor does it undertake any duty, to update this information to reflect future events or circumstances.

 

Company Contact:
Jim Frakes
Chief Executive Officer and Chief Financial Officer
Aethlon Medical, Inc.
Jfrakes@aethlonmedical.com

 

Investor Contact:
Susan Noonan
S.A. Noonan Communications, LLC
susan@sanoonan.com  

 

Aethlon Medical Inc. (Nasdaq:AEMD) is a featured biotech stock on Investorideas.com

 

More info on AEMD at Investorideas.com Visit: 

https://www.investorideas.com/CO/AEMD/

 

Get News Alerts on Aethlon Medical

 

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. Disclosure: Aethlon Medical, Inc. (NASDAQ:AEMD) is a paid featured stock on Investorideas.com More disclaimer info:  https://www.investorideas.com/About/News/Clientspecifics.asp  https://www.investorideas.com/About/Disclaimer.asp

Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

 

 

Biotech Industry Stocks- investing ideas in biotechnology stocks, medical technology and life sciences

Get more biotech and medical tech news, articles, podcasts and stock directories

 

 

October IPOs in Biotech, Cleantech, Transportation, Retail and Homebuilder Sectors (Nasdaq: $CAMP) (NASDAQ: $UPB) (Nasdaq: $CBLL) (NASDAQ: $SKYQ) (NYSE: $SARO) (Nasdaq: $PTLE) (NASDAQ: $HTLM) (NASDAQ: $SPHL)

October IPOs in Biotech, Cleantech, Transportation, Retail and Homebuilder Sectors (Nasdaq: $CAMP) (NASDAQ: $UPB) (Nasdaq: $CBLL) (NASDAQ: $SKYQ) (NYSE: $SARO) (Nasdaq: $PTLE) (NASDAQ: $HTLM) (NASDAQ: $SPHL)

 

 

 

 

November 8, 2024 – (Investorideas.com Newswire) Investorideas.com, a global news source and expert investing resource, announces today’s roundup of stocks to watch in the Biotech, Cleantech, Transportation, Retail and Homebuilder sectors.

 

All new companies are recent Nasdaq/NYSE IPOs.

 

Read this in full at https://www.investorideas.com/news/2024/main/11081IPOs.asp

 

Investor Ideas is always researching and searching for new stocks to add to our growing list of free stock directories. The directories are not meant as recommendations but as a research tool to discover opportunities and trading ideas in a particular sector.

 

New Stocks Added to the Biotech Directories:

Camp4 Therapeutics Corp (Nasdaq:CAMP) is developing disease-modifying treatments for a broad range of genetic diseases where amplifying healthy protein may offer therapeutic benefits. Our approach amplifies mRNA by harnessing a fundamental mechanism of how genes are controlled. To amplify mRNA, our therapeutic ASO drug candidates target regulatory RNAs (regRNAs), which act locally on transcription factors and are the master regulators of gene expression. CAMP4’s proprietary RAP Platform™ enables the mapping of regRNAs and generation of therapeutic candidates designed to target the regRNAs associated with genes underlying haploinsufficient and recessive partial loss-of-function disorders, of which there are more than 1,200, in which a modest increase in protein expression may have the potential to be clinically meaningful.

 

Upstream Bio, Inc. (NASDAQ:UPB) is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. The Company is developing verekitug, the only known antagonist currently in development that targets the receptor for thymic stromal lymphopoietin, a cytokine which is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune mediated diseases. The Company has advanced this highly potent monoclonal antibody into separate Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps, and plans to initiate development in chronic obstructive pulmonary disease. Upstream Bio’s team is committed to maximizing verekitug’s unique attributes to address the substantial unmet needs for patients underserved by today’s standard of care.

 

Ceribell, Inc. (Nasdaq:CBLL) is a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. The Ceribell System is an AI-powered, rapidly deployable point-of-care electroencephalography ("EEG") platform designed to address the unmet needs of patients in the acute care setting. The company is headquartered in Sunnyvale, Calif.

 

New Stocks Added to the Cleantech Directories:

Sky Quarry Inc. (NASDAQ:SKYQ) and its subsidiaries are, collectively, an oil production, refining, and a development-stage environmental remediation company formed to deploy technologies to facilitate the recycling of waste asphalt shingles and remediation of oil-saturated sands and soils. Our waste-to-energy mission is to repurpose and upcycle millions of tons of asphalt shingle waste, diverting them from landfills. By doing so, we can contribute to improved waste management, promote resource efficiency, conserve natural resources, and reduce environmental impact.

 

New Stocks Added to the Transportation Directories:

StandardAero, Inc. (NYSE:SARO) is a leading independent pure-play provider of aerospace engine aftermarket services for fixed and rotary wing aircraft, serving the commercial, military and business aviation end markets. StandardAero provides a comprehensive suite of critical, value-added aftermarket solutions, including engine maintenance, repair and overhaul, engine component repair, on-wing and field service support, asset management and engineering solutions. StandardAero is majority owned by global investment firm Carlyle (NASDAQ: CG).

 

PTL Ltd.  (Nasdaq: PTLE ) Headquartered in Hong Kong, we are an established bunkering facilitator providing marine fuel logistics services for vessel refueling, primarily container ships, bulk carriers, general cargo vessels, and chemical tankers. Targeting and serving the Asia Pacific market, we leverage our close relationships and partnership within our established network in the marine fuel logistic industry, including the upstream suppliers and downstream customers, to provide a one-stop solution for vessel refueling.

 

New Stocks Added to the Retail Directories:

HomesToLife Ltd (NASDAQ:HTLM) wholly owned subsidiary and operating company, HomesToLife Singapore, is one of the leading home furniture retailers that offers and sells customized furniture solutions in Singapore. As of October 2024, it has six retail store locations. It has helped homeowners create living spaces that reflect their individuality since 2014. Its product offerings include leather and fabric upholstered furniture, case goods and accessories, and offers a one-stop shop for retail customers to furnish their homes. “HomesToLife” has a long-standing pledge to offer fair prices, great value, consistent and reliable quality, and on-time delivery to its customers. The Company’s website, www.homestolife.com , offers consumers a seamless shopping experience online and post-sales customer service support.

 

New Stocks Added to the Homebuilder Directories:

SPRINGVIEW HOLDINGS LTD (NASDAQ:SPHL) designs and constructs residential and commercial buildings in Singapore. With an operating history dating back to 2002, the Company has established a positive reputation in the busy Singapore real estate development market through customer relationships. Springview’s projects cover four main types of work: (i) new construction, (ii) reconstruction, (iii) additions and alterations (A&A), and (iv) other general contracting services. Springview serves individual and independent homeowners in Singapore. With a skilled in-house team of experts, the Company provides a one-stop solution that fosters strong customer relationships, offering a comprehensive range of services such as design, construction, furniture customization and project management. The Company also offers post-project services, including defect repairs and maintenance, that further enhances its customer engagement and future project opportunities.

 

About Investorideas.com - Big Investing Ideas

Investorideas.com is the go-to platform for big investing ideas. From breaking stock news to top-rated investing podcasts, we cover it all. Our original branded content includes podcasts such as Exploring Mining, Cleantech, Crypto Corner, Cannabis News, and the AI Eye. We also create free investor stock directories for various sectors, including gaming, biotech, tech and sports. Public companies within the sectors we cover can use our news publishing and content creation services to help tell their story to interested investors. Paid content is always disclosed.

 

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/

Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

 

Learn more about our news, PR and social media, podcast and ticker tag services at Investorideas.com

https://www.investorideas.com/Investors/Services.asp

 

Learn more about advertising and guest posts

https://www.investorideas.com/Advertise/

 

Follow us on Twitter (X) https://X.com/Investorideas

Follow us on Facebook https://www.facebook.com/Investorideas

Follow us on YouTube https://www.youtube.com/c/Investorideas

 

Contact Investorideas.com to be added to our stock directories or learn more about us

Dawn Van Zant and Cali Van Zant

 

800 665 0411

 

 

 

 

 

 

 

 

 

Breaking Cleantech Automotive Stock News: Worksport Ltd. (NASDAQ: $WKSP) Announces Q3 2024 Earnings Conference Call on November 13th; @WorksportLtd

Breaking Cleantech Automotive Stock News: Worksport Ltd. (NASDAQ: $WKSP) Announces Q3 2024 Earnings Conference Call on November 13^th; @WorksportLtd

 

Company Invites Investors and Analysts to Discover Compelling Financial Updates and Growth Outlook

 

West Seneca, New York - November 7, 2024 (Investorideas.com Newswire) Worksport Ltd. (NASDAQ: WKSP) ("Worksport" or the "Company"), a U.S.-based manufacturer and innovator of hybrid and clean energy solutions for the light truck, overlanding, and global consumer goods sectors is excited to announce its Q3 2024 live earnings call scheduled for November 13, 2024, at 4:30 PM ET. This call will be conducted online and will include a detailed discussion of the Company’s performance, recent growth trends, and forward-looking insights.

 

Invitation to Analysts and Investors

Worksport invites analysts, investors, and media to join the live earnings call. This event will provide a comprehensive overview of its Q3 2024 results and offer a platform for direct engagement with the Company's leadership.

 

Call Details

Date: November 13, 2024
Time: 4:30 PM ET
Participation: To join the live call, please visit WKSP Q3 Earnings Call to register now.

 

Worksport encourages attendees to share the earnings call invite within their network.

 

Worksport Management is excited to share the story.

 

Expected Topics

In Q3 2024, the Company has had significant developments and milestones. While specific details will be shared during the call, attendees can look forward to insights into our recent achievements, strategic initiatives, and projected path to cash flow positivity. This includes updates on the Company's ongoing sales growth, future product launches, and 2025 growth trajectory. The Company will also provide an update to its financial guidance.

 

Paid News dissemination for Worksport Ltd.

 

Read this news, featuring WKSP in full at https://www.investorideas.com/news/2024/11071WKSP-Q3-Earnings-Conference-Call.asp

 

CEO's Statement

"We are thrilled to invite investors and analysts to our Q3 live earnings call," said Steven Rossi, CEO of Worksport. "We started mass production in January 2024 and initiated our sales push in March 2024. Now, we are on the cusp of launching multiple new product lines. The Company is laser-focused on continuing sales growth and achieving cash flow positivity, and we are eager to share the details of our progress and future plans. We confidently believe that the Company is undervalued and that growth will continue."

 

Investor Inquiries May Be Directed To:

Investor Relations, Worksport Ltd.
T: 1 (888) 554-8789 x128
W1: https://investor.worksport.com
W2: www.worksport.com
E: investors@worksport.com

 

Key 2024 Press-Releases:

• October 17: Nasdaq Grants Extension To Regain Compliance
• October 17: $2MM+ Projected Savings From New Strategic Initiative
• October 3: Commencing U.S Government Sales
• September 30: Update On ISO Certification
• September 19: Alpha Launch of SOLIS & COR
• September 12: Record High August Sales
• September 11: Worksport COR as an EV Range Extender for Tesla Model 3
• August 14: Record High Revenues; 275% Q2 Growth
• August 1: Impressive SOLIS Solar Cover Test Results
• May 8: Worksport Awarded $2.8MM Grant

Read all Worksport press releases: [Link to All Press Releases].

 

Stay Connected

• Investor Newsletter: Investors and customers are invited to follow Worksport's progress as it builds on this momentum and strives to redefine industry standards with each new corporate development. Link to Newsletter
• Contact Information

 

Investor Relations, Worksport Ltd. T: 1 (888) 554-8789 -128 W: investors.worksport.com E: investors@worksport.com
W: worksport.com

 

About Worksport

Worksport Ltd. (Nasdaq: WKSP), through its subsidiaries, designs, develops, manufactures, and owns the intellectual property on a variety of tonneau covers, solar integrations, and NP (Non-Parasitic), hydrogen-based true green energy solutions for the sustainable, clean energy, and automotive industries. Worksport has an active partnership with Hyundai for the SOLIS Solar cover. Additionally, Worksport's hard-folding cover, designed and manufactured in-house, is compatible with RAM, Chevrolet, and GMC models from General Motors, as well as Ford, Jeep, Nissan, and Toyota pickup trucks. Worksport seeks to capitalize on the growing shift of consumer mindsets towards clean energy integrations with its proprietary solar solutions, mobile energy storage systems (ESS), and NP (Non-Parasitic), Hydrogen-based technology.

Terravis Energy's website is terravisenergy.com. For more information, please visit investors.worksport.com.

 

Connect with Worksport

Please follow the Company's social media accounts on X (previously Twitter), Facebook, LinkedIn, YouTube, and Instagram (collectively, the "Accounts"), the links of which are links to external third party websites, as well as sign up for the Company's newsletters at investors.worksport.com. The Company does not endorse, ensure the accuracy of, or accept any responsibility for any content on these third-party websites other than content published by the Company.

 

Product social media

Instagram
Facebook
YouTube

 

Investor social media

X (formerly Twitter)
LinkedIn
Link to Newsletter

 

Investors and others should note that the Company announces material financial information to our investors using our investor relations website, press releases, Securities and Exchange Commission ("SEC") filings, and public conference calls and webcasts. The Company also uses social media to announce Company news and other information. The Company encourages investors, the media, and others to review the information the Company publishes on social media.

 

The Company does not selectively disclose material non-public information on social media. If there is any significant financial information, the Company will release it broadly to the public through a press release or SEC filing prior to publishing it on social media.

 

For additional information, please contact:
Investor Relations, Worksport Ltd. T: 1 (888) 554-8789 -128 W: investors.worksport.com W: www.worksport.com E: investors@worksport.com

 

Forward-Looking Statements
The information contained herein may contain "forward looking statements." Forward looking statements reflect the current view about future events. When used in this press release, the words "anticipate," "believe," "estimate," "expect," "future," "intend," "plan," "project," "should," or the negative of these terms and similar expressions, as they relate to us or our management, identify forward looking statements. These statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: (i) supply chain delays; (ii) acceptance of our products by consumers; (iii) delays in or nonacceptance by third parties to sell our products; and (iv) competition from other producers of similar products. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the SEC, including, without limitation, our Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC's web site at www.sec.gov. As a result of these matters, changes in facts, assumptions not being realized or other circumstances, the Company's actual results may differ materially from the expected results discussed in the forward-looking statements contained in this press release. The forward-looking statements made in this press release are made only as of the date of this press release, and the Company undertakes no obligation to update them to reflect subsequent events or circumstances.

 

Worksport Ltd. (Nasdaq: WKSP) is a featured renewable energy/automotive stock on Investorideas.com

 

More info on WKSP at Investorideas.com Visit:  https://www.investorideas.com/CO/WKSP/

 

Disclaimer/Disclosure: Disclosure: Worksport Ltd. (Nasdaq: WKSP) is a paid featured company on Investorideas.com effective  October 18^th 2024 for 2 months. lInvestorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. Contact management and IR of each company directly regarding specific questions. More disclosure info can be found here. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

 

 

Get more Renewable Energy Stock news, articles, podcasts and Stock Directories

 

 

 

 

 

 

Get more Automotive Stocks Investor Ideas – news, articles and stock directories